MedTrace Logo

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

NCT03314207 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2023-01-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate subjects with X-linked retinitis pigmentosa caused by RPGR-ORF15 mutations in a clinical setting to fully characterize their condition, measure testing variability, and estimate rates of progression of clinical parameters.

Conditions

  • X-Linked Retinitis Pigmentosa

Sponsors & Collaborators

  • Beacon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Matthew Feinsod, MD · Applied Genetics Technologies Corporation

Eligibility

Min Age
6 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2022-02-10
Completion
2022-02-10

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03314207 on ClinicalTrials.gov